Fulcrum Therapeutics

Fulcrum Therapeutics

Yahoo Finance • last month

Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares fell approximately 50% on June 1, 2026, after the company disclosed that the FDA had raised class-wide safety concerns about PRC2-targeting agen... Full story

Yahoo Finance • last month

Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities laws. The investigation focuses on inve... Full story

Yahoo Finance • last month

This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’

Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns. Continue Reading... Full story

Yahoo Finance • last month

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik®(tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (... Full story

Yahoo Finance • 3 months ago

Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations

medical research 16 ©Rawpixel Fulcrum Therapeutics Inc. (NASDAQ:FULC) moved higher in pre-market trading on Monday after reporting first-quarter results that topped analyst expectations. The clinical-stage biopharmaceutical firm posted a... Full story

Yahoo Finance • 3 months ago

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hema... Full story

Yahoo Finance • 3 months ago

Pre-Market Earnings Report for April 27, 2026 : VZ, DPZ, ARLP, LKFN, HBT, BFST, FULC, BMRC, NWFL

The following companies are expected to report earnings prior to market open on 04/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Verizon Communications Inc. (VZ)is reporting for the quarter ending... Full story

Yahoo Finance • 4 months ago

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease 

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national v... Full story

Yahoo Finance • 4 months ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined r... Full story

Yahoo Finance • 4 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genet... Full story

Yahoo Finance • 5 months ago

Fulcrum Therapeutics move lower ‘overdone,’ says Stifel

Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF may comfortably be greater than 20% give... Full story

Yahoo Finance • 7 months ago

Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants

* Fulcrum Therapeutics (FULC [https://seekingalpha.com/symbol/FULC]) on Wednesday announced the pricing of its underwritten public offering of 11.85M shares of its common stock at a public offering price of $13.50 per share, and, in lieu... Full story

Yahoo Finance • 7 months ago

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneticall... Full story

Yahoo Finance • 7 months ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg coh... Full story

Yahoo Finance • 8 months ago

Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: HSBC upgraded Caterpillar (CAT) to Buy... Full story

Yahoo Finance • 8 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to prov... Full story

Yahoo Finance • 9 months ago

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story

Yahoo Finance • 11 months ago

Neogen Corporation (NEOG): A Bull Case Theory

We came across a bullish thesis on Neogen Corporation on Cornerstone Value’s Substack. In this article, we will summarize the bulls’ thesis on NEOG. Neogen Corporation's share was trading at $5.60 as of August 25th. NEOG’s trailing and for... Full story

Yahoo Finance • 11 months ago

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with geneti... Full story

Yahoo Finance • 11 months ago

Noteworthy Tuesday Option Activity: PII, FULC, OXY

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Polaris Inc (Symbol: PII), where a total volume of 9,756 contracts has been traded thus far today, a contract volume whic... Full story